Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 0904-7359

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 0904-7359). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton Label (Image 01)

Label for Major Pharmaceuticals Lurasidone Hydrochloride tablets, 20 mg strength, oral film-coated tablets. The unit dose package contains 30 tablets (3 blister packs of 10). Includes storage instructions and dispensing guidance. NDC 0904-7355-04 is displayed with barcode and labeler information from Major Pharmaceuticals, Indianapolis, Indiana.*

FDA Label Image

Carton Label (Image 02)

Label for lurasidone hydrochloride 40 mg film-coated tablets by Major Pharmaceuticals. The label shows the NDC 0904-7356-61, indicates a unit dose package of 100 tablets (10 x 10), and includes instructions to dispense with a medication guide. Storage conditions are specified as 25°C (77°F) with allowed excursions, and the container is to be kept tightly closed and out of reach of children. The label also notes the product is Rx only and is for institutional use only.*

FDA Label Image

Carton Label (Image 03)

Packaging label for lurasidone hydrochloride 60 mg film-coated tablets by Major Pharmaceuticals. The label indicates a unit dose package containing 100 tablets (10 x 10), with directions to dispense with medication guide and storage instructions at controlled room temperature. The NDC number is 0904-7357-61, and the product is prescription only.*

FDA Label Image

Carton Label (Image 04)

Lurasidone Hydrochloride 80 mg oral tablets by Major Pharmaceuticals. This unit dose packaging contains 100 film-coated tablets (10 packs of 10 tablets). The label includes dispensing instructions, storage conditions, and safety information, noting that the product is Rx only and should be used under professional guidance.*

FDA Label Image

Carton Label (Image 05)

Label for Lurasidone Hydrochloride 120 mg film-coated tablets by Major Pharmaceuticals. The unit dose packaging contains 30 tablets (3 x 10). It includes dispensing instructions, storage conditions at 25°C with allowed excursions, and a note that the drug is for institutional use only. The label displays the NDC 0904-7359-04 and highlights prescription-only status.*

FDA Label Image

Lurasidone-structure (Lurasidone 1)

Chemical structure of lurasidone hydrochloride, showing its molecular layout with rings, bonds, and an HCl component.*

FDA Label Image

Lurasidone-fig2 (Lurasidone Fig2)

A chart titled Impact of other drugs on Lurasidone Pharmacokinetics (PK) showing fold changes and 90% confidence intervals for Cmax and AUC when lurasidone is co-administered with strong CYP3A4 inhibitors (ketoconazole 400 mg/day), moderate CYP3A4 inhibitors (diltiazem 240 mg/day), and strong CYP3A4 inducers (rifampin 600 mg/day and lithium 600 mg BID). The x-axis displays change relative to lurasidone alone ranging from -4 to 4 fold.*

FDA Label Image

Lurasidone-fig2 (Lurasidone Fig3)

A forest plot chart illustrating the pharmacokinetic interactions of lurasidone hydrochloride with various interacting drugs. It displays fold changes and 90% confidence intervals for parameters such as Cmax, AUC, and trough levels relative to the interacting drug alone, including drugs like Digoxin, Midazolam, oral contraceptives (Ethinyl Estradiol, Norelgestromin), and Lithium.*

FDA Label Image

Lurasidone-fig3 (Lurasidone Fig4)

A dot plot chart illustrating fold changes with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC across different groups. The groups include varying degrees of renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population descriptions by gender (females) and race (Asian). The x-axis represents change relative to reference, ranging from 0 to 6.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.